All Articles

HCW Biologics executes a reverse stock split to avoid Nasdaq delisting. Is it a necessary survival tactic or a warning sign for investors? We analyze.

After years as a national embarrassment, 24 Sussex Drive is getting a lifeline. The plan is more than a renovation; it’s a strategic pivot to private funding.

Medicenna Therapeutics is advancing its promising cancer immunotherapies, MDNA11 and MDNA113, while navigating a tight financial runway. Can it deliver?

Maalexi just closed a $2.8M round led by Saudi's top insurer to build a regulated crypto exchange for crops. Is this the future of global food security?

FactSet's new AI tool promises to democratize portfolio analytics. But in a high-stakes industry, can it deliver powerful insights without sacrificing trust?

Lupin's generic approval for Xtandi isn't just about price. Its new single-pill dose could transform patient care and challenge Astellas's market dominance.

CDT Equity's bet on SarborgQ signals a new era where quantum computing and AI accelerate drug formulation, creating a high-stakes race for intellectual property.

Asia's largest home furnishing firm just launched an AI that designs entire homes in 30 minutes, linking plans directly to its massive robot factories.

reAlpha Mortgage is ditching traditional commissions for a flat-fee model with stock options and AI. A bold commercialization play in the war for loan officers.

New research reveals that even with pensions, government workers need more. Financial guidance, digital tools, and literacy are key to true confidence.

A small biotech's dual-front war on cancer reveals a powerful new playbook: leveraging elite partnerships to pioneer a preventative vaccine and a novel CAR-T.

A new customs deal with Uruguay isn't just stopping smugglers. It's a key move to secure supply chains, de-risk a $317M trade route, and pave the way for a larger FTA with South America's MERCOSUR bloc.

A proxy fight pits Vaxart's experienced board against dissident shareholders demanding accountability, with the future of its innovative pill vaccines at stake.

A new Redfin survey reveals overwhelming bipartisan support for housing affordability policies, creating a powerful public mandate for a landmark bill now stalled.

In a first for muscular dystrophy, Epicrispr's EPI-321 didn't just slow the disease—it increased lean muscle volume, signaling a new era for gene therapy.

Upexi joins the Russell Microcap Index, a milestone for any firm. But with a treasury heavy on volatile Solana, is this a new model for investors or a cautionary tale?

How did a single Korean serum dethrone skincare giants on Amazon? Meditherapy's rise reveals a new blueprint for brand building in the digital age.

Nasdaq-listed Jinxin Technology is betting its future on AI companions, moving from content to hardware to capture a slice of China's booming children's AI market.

First Responders Children's Foundation and T-Mobile are disrupting recognition by letting the public nominate heroes, a strategic shift in community engagement.

The Subaru Ascent's top quality award is more than a trophy. It's a look into how corporate values, from the factory floor to the family car, build trust.